P
NXTC icon

Pfizer’s NextCure NXTC Stock Holding History

Pfizer’s Portfolio NXTC Stock Details NXTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$73K Sell
44,347
-109,007
-71% -$806K 0.04% 15
2026
Q1 		$1.54M Sell
153,354
-4,292
-3% -$52.4K 0.64% 13
2025
Q4 		$2.24M Hold
157,646
– – 0.95% 12
2025
Q3 		$924K Buy
157,646
+144,509
+1,100% +$756K 0.21% 15
2025
Q2 		$870K Sell
13,137
-144,510
-92% -$776K 0.15% 16
2025
Q1 		$909K Buy
157,647
+36,101
+30% +$318K 0.18% 17
2024
Q4 		$1.89M Buy
+121,546
New +$1.79M 0.07% 18

Other funds holding NXTC

IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
VA
Verdad Advisers Boston, Massachusetts $104M AUM
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

Pfizer's NXTC Position: Q2 2026 in Review

Pfizer reduced its NextCure (NXTC) stake by 71% in Q2 2026, selling an estimated $806K and leaving 44,347 shares worth $73K. The position accounts for 0.04% of the portfolio, ranked #15.

Pfizer first reported a position in NXTC in Q4 2024 and has held it in 7 quarters since. The position peaked at $2.24M in Q4 2025. 30 funds tracked by Wall St. Rank hold NXTC as of Q2 2026.

  • Pfizer held 44,347 shares of NextCure worth $73K as of Q2 2026.
  • Pfizer sold 109,007 NextCure shares in Q2 2026, an estimated $806K.
  • NextCure made up 0.04% of Pfizer's portfolio in Q2 2026, its #15 holding.
  • Pfizer first reported a position in NextCure in Q4 2024 and has held it in 7 quarters since.
  • Pfizer's NextCure position peaked at $2.24M in Q4 2025.
  • 30 funds tracked by Wall St. Rank held NextCure as of Q2 2026.

Based on Pfizer's 13F filing for Q2 2026, filed 13 Aug 2026.